Short description
Aldexa Therapeutics develops treatments for the dry form of age-related macular degeneration eye disease.
Description
Aldexa Therapeutics, Inc. develops treatments for the dry form of age-related macular degeneration eye disease that may lead to blindness. It activities include the development of drugs to inhibit the formation of toxic metabolites that accumulate in the back of the eye. Aldexa Therapeutics, Inc. was formerly known as Neuron Systems, Inc. The company was incorporated in 2004 and is based in Burlington, Massachusetts. The company changed its name to Aldeyra Therapeutics, Inc. on March 17, 2014. Aldeyra held an initial public offering on May 7, 2014.
Total funding
$$2020202
Sign in for full access
Location
Burlington, Massachusetts, United States, North America
Founded on
January 1, 2004
Non-profit?
No
Acquired?
No
Employees count
1-10
Founders
John E. Dowling, Thomas A. Jordan